Track topics on Twitter Track topics that are important to you
Bimekizumab is a monoclonal antibody that selectively neutralises interleukin 17A and interleukin 17F, so is being tested for people with psoriatic arthritis. The latest findings, reported in the Lancet, are encouraging. A total of 206 people with psoriatic arthritis were split into groups: 42 people were in a placebo group and the others received varying […]
The post Novel therapy – bimekizumab – potential psoriatic arthritis treatment appeared first on Arthritis Digest.
Original Article: Novel therapy – bimekizumab – potential psoriatic arthritis treatmentNEXT ARTICLE
An antibody is a protein produced by the body's immune system when it detects harmful substances, called antigens. Examples of antigens include microorganisms (such as bacteria, fungi, parasites, and viruses) and chemicals. Antibodies may be produc...
Arthritis Fibromyalgia Gout Lupus Rheumatic Rheumatology is the medical specialty concerned with the diagnosis and management of disease involving joints, tendons, muscles, ligaments and associated structures (Oxford Medical Diction...
According to the National Arthritis Data Workgroup, an estimated 6 million people in the United States report having experienced gout at some point in their lives. In fact, gout is the most common form of inflammatory arthritis in men over the age of 40....